About: Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.87 (-24.58%)
CHRS NASDAQ Coherus BioSciences Inc
Coherus BioSciences Inc share price
Atividade de preço de CHRS
Último preço
$ 0,870
Variação (24h)
-0,29 USD (24,58%)
Volume
3.31M
Volume (média 4 sem.)
-
Abertura
$ 1,15
Variação do dia
$ 0,81 - $ 1,15
Fechamento anterior
$ 1,16
Último negócio
29 Oct, 2:50 pm GMT+0
Atrasado
29 Oct, 2:50 pm GMT+0
CHRS price performance
Atrasado
29 Oct, 2:50 pm GMT+0
quote.marketSignals